Uscom Quarterly Report at 31st March 2021

Uscom Q3 FY21 4C Report

"Q3 sales and receipts remain strong but down due to the impact of the Chinese New Year, effecting Chino activity for 6 weeks, while both European and US activities remained constrained by the pandemic. Hungary has effectively been closed for the quarter and our US team are still unable to attend hospitals and clinics. However we remain cash flow positive for the YTD, supported by strong Chino sales. Going forward management noted the 18.3% GDP growth in Chino for the March quarter and look forward to this growth converting into health spending. Europe and the US have also begun tentative recoveries with healthy soles prospects starting to emerge. Additionally the Uscom BP+ has just received NMPA regulatory approval initiating an additional revenue stream for Uscom China. The SpiroSonic AIR continues its CE and FDA regulatory progress, which has also been significantly delayed due to the pandemic. These approvals, once received, are anticipated to stimulate revenue over the next 12 months, particularly as global economies resume normal medical business."

Prof. Rob Phillips

Uscom has released its Appendix 4C - cash flow report for the quarter ending 31st March 2021.

  • Cash receipts $0.89m (down 53%) from $1.91m 
  • Sales revenue $0.78m (down 20%) from $0.98m 
  • Cash on hand $2.03m, down $0.25m
  • YTD Cash receipts $4.2m 
  • YTD cash flow positive $0.11m
BACK TO TOP